Corcept Therapeutics
CORT
63.62
-1.36
-2.09%
Corcept Therapeutics
US · CORT
#1285 by market cap
Listed 1970
63.62
-1.36
-2.09%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Recent news
-
Company notice
Columbia Banking System | 4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-Officer O'HAVER CORT LSEC · 2025/3/15
-
Piper Sandler Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $165Market Newswire · 2026/10/26
-
Rating change
Truist Financial Initiates Corcept Therapeutics(CORT.US) With Buy Rating, Announces Target Price $164Market Newswire · 2026/8/18
-
Rating change
Piper Sandler Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $88Market Newswire · 2026/6/1
-
Rating change
Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE), Vertex Pharmaceuticals (VRTX) and Corcept Therapeutics (CORT)TipRanks · 2026/10/15
-
Rating change
H.C. Wainwright Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $95Market Newswire · 2026/6/2
-
Rating change
H.C. Wainwright Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Raises Target Price to $165Market Newswire · 2026/7/30
-
Company notice
Columbia Banking System | 4: Statement of changes in beneficial ownership of securities-Officer O'HAVER CORT LSEC · 2024/4/24
-
CCORF Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $161Market Newswire · 2026/11/5
-
Rating change
CCORF Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Raises Target Price to $161Market Newswire · 2026/7/29
-
GUIDANCE: (CORT) Corcept Therapeutics Reiterates 2026 Revenue Guidance of $1.1B-$1.2B, Vs. FactSet Est of $1.15BMT Newswires · 2026/11/4
-
H.C. Wainwright Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $165Market Newswire · 2026/11/6
-
Rating change
CCORF Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $135Market Newswire · 2026/7/9
-
Company notice
Columbia Banking System | 4: Statement of changes in beneficial ownership of securities-Officer O'HAVER CORT LSEC · 2025/2/27
-
Company notice
Columbia Banking System | 4: Statement of changes in beneficial ownership of securities-Officer O'HAVER CORT LSEC · 2025/3/5
-
Rating change
Piper Sandler Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Raises Target Price to $165Market Newswire · 2026/7/30
-
Rating change
Wolfe Research Downgrades Corcept Therapeutics(CORT.US) to Sell Rating, Announces Target Price $50Market Newswire · 2026/7/27
-
Company notice
Columbia Banking System | 4: Statement of changes in beneficial ownership of securities-Officer O'HAVER CORT LSEC · 2025/2/19
-
Piper Sandler Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Raises Target Price to $173Market Newswire · 2026/11/4
-
Rating change
Wolfe Research Maintains Corcept Therapeutics(CORT.US) With Sell Rating, Maintains Target Price $50Market Newswire · 2026/7/30
-
Form 144 | Corcept Therapeutics(CORT.US) Director Proposes to Sell 3.34 Million in Common StocksMarket Newswire · 2026/9/15
-
Piper Sandler Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $165Market Newswire · 2026/10/19
-
Rating change
CCORF Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $110Market Newswire · 2026/5/4
-
Rating change
CCORF Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Raises Target Price to $135Market Newswire · 2026/5/28
-
Rating change
H.C. Wainwright Keeps Their Buy Rating on Corcept Therapeutics (CORT)TipRanks · 2026/6/1
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Corcept Therapeutics discussion 0 comments